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Dietary fat overconsumption leads to myocardial lipid
accumulation through mechanisms that are incompletely
resolved. Previously, we identified increased transloca-
tion of the fatty acid transporter CD36 from its endosomal
storage compartment to the sarcolemma as the primary
mechanism of excessive myocellular lipid import. Here,
we show that increased CD36 translocation is caused
by alkalinization of endosomes resulting from inhibition
of proton pumping activity of vacuolar-type H+-ATPase
(v-ATPase). Endosomal alkalinization was observed in
hearts from rats fed a lard-based high-fat diet and in
rodent and human cardiomyocytes upon palmitate over-
exposure, and appeared as an early lipid-induced event
preceding the onset of insulin resistance. Either genetic
or pharmacological inhibition of v-ATPase in cardiomyo-
cytes exposed to low palmitate concentrations reduced
insulin sensitivity and cardiomyocyte contractility,
which was rescued by CD36 silencing. The mechanism
of palmitate-induced v-ATPase inhibition involved its
dissociation into two parts: the cytosolic V1 and the in-
tegral membrane V0 subcomplex. Interestingly, oleate
also inhibits v-ATPase function, yielding triacylglycerol
accumulation but not insulin resistance. In conclusion,
lipid oversupply increases CD36-mediated lipid uptake
that directly impairs v-ATPase function. This feeds
forward to enhanced CD36 translocation and further in-
creased lipid uptake. In the case of palmitate, its accelera-
ted uptake ultimately precipitates into cardiac insulin
resistance and contractile dysfunction.
Overconsumption of lipids is associated with high risks of
developing heart failure (1,2). The heart exposed to high
lipid concentrations displays elevated rates of long-chain
fatty acid (LCFA) uptake, which often exceeds the capacity
of the mitochondria to oxidize the LCFA so that lipids
accumulate inside the cardiomyocytes (3,4). Lipid oversup-
ply induces mitochondrial dysfunction over time, thereby
aggravating the mismatch between LCFA uptake and oxi-
dation (3,5). Lipid oversupply in combination with other
factors, such as high sucrose consumption, may ultimately
lead to contractile dysfunction (5). Importantly, the mech-
anisms of chronically elevated LCFA uptake involve altered
dynamics of LCFA transporters (3).
Whereas the heart expresses four membrane LCFA
transporters (CD36, FABPpm, FATP1, and FATP4), studies
with CD36-null animals demonstrate that ;70% of cardiac
LCFA uptake is mediated via CD36 (3). In the heart, CD36
is not only present at the sarcolemma but is also stored in
intracellular membrane compartments (endosomes), from
where it can translocate to the sarcolemma to increase
LCFA uptake (3). Insulin is the main hormonal stimulus
to induce CD36 translocation, leading to increased LCFA
uptake for subsequent storage into triacylglycerols (3,6).
Insulin-induced CD36 translocation closely resembles the
well-characterized insulin-induced GLUT4 translocation
from endosomes to the cell surface to increase cardiac glu-
cose uptake (3). Hence, CD36 translocation is a key regula-
tory mechanism of cardiac LCFA uptake.
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In insulin-resistant rodent models, CD36 has been
found responsible for the chronically elevated LCFA
influx upon lipid overload (7,8). Concordantly, CD36-
null mice are protected against the development of
lipid-induced cardiomyopathy (9,10). CD36 protein ex-
pression does not change during cardiac lipid overload.
Rather, the net translocation of CD36 from endosomes
to the sarcolemma is increased, indicating that lipid
oversupply induces chronic changes in subcellular
CD36 cycling. In rodent models of lipid-induced cardio-
myopathy, the chronically elevated uptake of LCFA into
cardiomyocytes is coupled to accumulation of triacylgly-
cerol within lipid droplets and formation of diacylgly-
cerols/ceramides (7,8). These lipid metabolites impair
insulin signaling at the level of insulin receptor substrate
1/2 or Akt2 (11), which then leads to inhibition of insulin-
stimulated GLUT4 translocation and glucose uptake (3,8).
Insulin resistance, therefore, would be expected to also im-
pair insulin-stimulated CD36 translocation and LCFA up-
take. However, CD36-dependent lipid uptake is highly
upregulated in the insulin-resistant heart. Hence, how
increased CD36 translocation evolves from lipid oversupply
remained elusive.
We previously obtained evidence that endosomal alka-
linization causes a rapid translocation of CD36, but not of
GLUT4, to the sarcolemma (12). By active import of pro-
tons, vacuolar-type H+-ATPase (v-ATPase) acidifies the lu-
men of vesicular organelles, among which are endosomes.
Themultimeric v-ATPase protein complex consists of 14 sub-
units: 6 subunits form the integral membrane subcomplex
V0, encompassing the proton channel, and 8 subunits make
up a peripheral membrane subcomplex V1, containing the
ATP-binding pocket (13–15).
In this study, we first analyzed v-ATPase function in
cardiomyocytes in vivo and in vitro during chronic lipid
oversupply. Secondly, we made a detailed assessment in
time of the onset of v-ATPase inhibition compared with
increased LCFA uptake and insulin resistance. Thirdly, we
studied whether genetic or pharmacological inhibition of
v-ATPase affects insulin resistance and contractile dysfunc-
tion and clarified the involvement of CD36. Fourthly, we
investigated functional alterations of v-ATPase in human
stem cell–derived cardiomyocytes subjected to excess lipids.
Finally, we determined the mechanism and LCFA specificity
of v-ATPase inhibition.
RESEARCH DESIGN AND METHODS
The experiments in this study were performed according to
Dutch regulations and approved by the Maastricht Uni-
versity Committee for Animal Welfare.
Experimental Animals and Isolation and Culturing
of Primary Rat Cardiomyocytes
Male Lewis rats (200–250 g) were purchased from
Charles River Laboratories and fed a 10% low-fat diet
(D12450B; Research Diets, New Brunswick, NJ) or a
60% high-fat diet (D12492). After 7 weeks of the diet,
cardiomyocytes were isolated as previously described
(16). For the in vitro studies, rats were fed standard
chow before the isolation of cardiomyocytes. Then, cultur-
ing was performed for #48 h in low-palmitate and high-
palmitate media as previously described (17). For selected
experiments, cultured primary cardiomyocytes were treated
with oleate replacing palmitate at the same concentrations
or with blocking antibodies against CD36 (clone 63, Bioceros
BV) as previously described (17). Extensive control experi-
ments using this antibody for CD36 blockade were published
previously (17).
Cell Culture of HL-1 Cardiomyocytes and Transfection
HL-1 cells were cultured in control medium as previously
described (18). We also used low-palmitate and high-palmitate
media containing 100 nmol/L insulin and 500 nmol/L
or 20mmol/L palmitate, respectively, complexed to 3.3mmol/L
BSA, resulting in palmitate-to-albumin ratios of 0.15:1
(low palmitate) and 6:1 (high palmitate). When indicated,
oleate was used instead of palmitate at the same concen-
trations. At 24 h after seeding, cells were transfected at
60–70% confluence using 10 pmol small interfering (si)
RNA and 2 mL Lipofectamine RNAiMAX per well in anti-
biotic- and noradrenaline-free culture medium. After 6 h,
medium was refreshed with growth medium, and 48 h
after transfection cell lysis or functional assays were per-
formed. In preparation of testing short-term insulin action,
media were removed and replaced by control medium. At
30 min thereafter, insulin (or an equal volume of H2O) was
added for another 30 min before the measurements, as de-
scribed below.
Human Induced Pluripotent Stem Cells Differentiated
Into Cardiomyocytes
Human induced pluripotent stem cells (iPSCs) were pro-
vided by Dr. F. van Tienen (Maastricht University Medical
Center) and differentiated into cardiomyocytes (iPSC-CMs)
according to the manufacturer’s protocol (Thermo Fisher
Scientific). All treatments on iPSC-CMs were performed as
indicated for HL-1 cardiomyocytes.
CD36 Cell Surface Staining
Two-photon microscopy to visualize cell surface CD36
localization and colorimetric CD36 detection at the sar-
colemma using a horseradish peroxidase–linked second-
ary antibody were performed as previously described
(17,19).
Measurement of Substrate Uptake
[1-14C]palmitate and [1-3H]deoxyglucose uptake into sus-
pensions of primary cardiomyocytes was measured as pre-
viously described (6). Uptake of these substrates into HL-1
cardiomyocytes and into cultured primary cardiomyocytes,
with both cell models seeded on precoated glass slides, was
measured as previously described (17,18).
Measurement of Triacylglycerol Content
Myocellular triacylglycerol accumulation was measured as
previously described (19).
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Measurement of Cellular Chloroquine Accumulation
as Readout of v-ATPase Function
Chloroquine accumulation was measured as previously
described (12).
Microscopical Imaging of Endosomal Acidification
Primary cardiomyocytes were cultured for 1.5 h in adhesion
medium and then incubated for 15 min with 500 nmol/L
LysoSensor DND-189 for subsequent imaging with a Leica
TCS SP5 (Leica Microsystems GmbH, Wetzlar, Germany) two-
photon microscope. Then, 100 nmol/L bafilomycin-A was
added, and a second image was captured. Excitation was at
820 nm, and a Leica objective HCX APO L320/1.00 was used
for excitation and epi-collection. LysoSensor Green (DND-189,
Invitrogen) fluorescence signal was detected at 470–550 nm.
Measurement of Cardiomyocytic Contraction
Dynamics
Contractile properties of cardiomyocytes were assessed at
1 Hz field stimulation using a video-based cell geometry
system to measure sarcomere dynamics (IonOptix). From the
digitized recordings, contractile parameters (sarcomere short-
ening, time to peak, and decay time) were calculated as
previously described (17).
Measurement of Colocalization of v-ATPase and CD36
Cardiomyocyte suspensions were subjected to subcellular
fractionation as previously described (6), yielding a low-
density microsomal fraction enriched in endosomes. Ali-
quots (100 mg) were incubated with anti-IgG, anti-CD36,
or anti–v-ATPase a2 antibodies overnight at 4°C in the
absence of detergents. Then, the antibody-captured low-
density microsomal vesicles were coupled to protein-A
Sepharose-4 beads for 4 h at 4°C. Further preparation of
the vesicles for analysis of coimmunoprecipitation was per-
formed as earlier described (18).
Measurement of v-ATPase Disassembly
Two methods were applied for analysis of disassembly.
1. Immunoprecipitation: HL-1 cardiomyocytes were washed
twice with ice-cold PBS and lysed with lysis buffer con-
taining 1% Brij O20, 250 mmol/L NaCl, 5 mmol/L EDTA,
and 50 mmol/L HEPES (pH 7.0). A 500 mg cell suspen-
sion was incubated overnight at 4°C with control IgG or
specific antibodies recognizing v-ATPase B2 or a2 sub-
units. The protein-antibody complex was coupled to
Sepharose-4 beads for 4 h at 4°C. Beads were washed
five times in lysis buffer, boiled in sample buffer, and
centrifuged, after which the supernatant was used for
Western blotting.
2. Fractionation: HL-1 cardiomyocytes were fractionated
into membrane and cytoplasmic fractions, as previously
described (20), for further analysis by Western blotting.
Cell Lysis and Western Blotting
Cell lysis and Western blotting were performed as described
earlier (6). Antibody details are provided in the Supplementary
Data online. The signals were normalized to caveolin-3 (load-
ing control). Then, a second normalization was performed by
setting the control incubation (low-fat diet, control, or low-
palmitate condition, depending on the experiment) at 1.
mRNA Expression of Cardiac-Specific Genes
Total RNA was isolated as previously described (10), and
quantitative real-time PCR was performed using SYBR Green
(Bio-Rad) and the following primer sequences (59→39):
CTCCGTGAAGGGATAACCAGG (MYH6-F), GGGCCTCTAG
ACGCTCCTT (MYH6-R), AGCGGAAAAGTGGGAAGAGG
(TNNT2-F), CACAGCTCCTTGGCCTTCTC (TNNT2-R), CAC
GAACCACGGCACTGATT (TBP-F), and TTTTCTTGCTGCCA
GTCTGGAC (TBP-R). Samples were normalized using TBP
as a housekeeping gene.
Statistics
All data are presented as mean 6 SEM. Statistical analysis
was performed by using two-sided Student t test, and we
applied paired testing when possible. P values of ,0.05
were considered statistically significant.
RESULTS
In the Rodent Heart, CD36 Colocalizes With v-ATPase
on Endosomes
Rat cardiomyocytes were fractionated for the purification of
the endosome-containing low-density microsomal fraction.
As anticipated, v-ATPase subunits a2 (as part of the
cytosolic V0 subcomplex) and B2 (as part of the integral
membrane V1 subcomplex) were both more prominently
present in the microsomal fraction compared with the total
cardiomyocyte lysate (Fig. 1A). This fraction was subse-
quently used for immunoprecipitation in the absence of
detergents (i.e., to keep the vesicular membranes intact).
Upon immunoprecipitation using CD36-directed antibodies,
all of the a2 subunit and most of the B2 subunit was found
in the pellet fraction, whereas no a2 and few B2 were found
in the supernatant fraction (Fig. 1A). In a reverse immuno-
precipitation, using antibodies against a2, CD36 was almost
completely captured as well as most of B2 (Fig. 1A). Hence,
under basal conditions, the majority of CD36 and v-ATPase
colocate to the same endosomal vesicles.
Lipotoxic Conditions Decrease v-ATPase Function
in Cardiomyocytes In Vivo and In Vitro
Lewis rats were fed a low-fat diet (10% fat) or a high-fat diet
(60% fat) for 7 weeks. As expected, body weight and heart
mass were significantly increased in the group fed the high-
fat diet (Supplementary Fig. 1A and B), whereas blood glucose
levels remained in the normal range (Supplementary Fig. 1C).
Upon subcellular fractionation, cardiomyocytes from rats fed
the high-fat diet displayed increased localization of CD36 at
the plasma membrane and decreased content in the low-
density microsomal fraction (that includes endosomes).
GLUT4 localization showed the opposite response: in-
creased low-density microsomal and decreased plasma
membrane abundance (Supplementary Fig. 1D). Hence,
in the high-fat diet condition, CD36 preferentially trans-
located to the sarcolemma, whereas GLUT4 internalized
diabetes.diabetesjournals.org Liu and Associates 1523
Figure 1—High-fat diet impairs v-ATPase function in cardiomyocytes. A: Immunoprecipitation (IP) of CD36 or v-ATPase subunit a2 or IgG
control from low-density microsomal (LDM) fractions (enriched in endosomes) prepared from primary rat cardiomyocytes. IP samples were
immunoblotted with antibodies against CD36 and v-ATPase subunits a2 and B2. Lys, cardiomyocyte lysates; P, pellet of IP; S, supernatant
of IP. Immunoblots are representative results (n = 3). B–K: Cardiomyocytes were isolated from Lewis rats after being fed a low-fat diet (LFD)
or high-fat diet (HFD) for 7 weeks. B and C: CD36 and GLUT4 presence in cell lysate (Lys), at the plasma membrane fraction (PM), and in the
LDM fraction after subcellular fractionation (n = 3). D and E: LCFA and glucose uptake into cardiomyocytes treated without/with insulin (Ins)
or bafilomycin-A (BafA) for 15 min (LFD: n = 6; HFD: n = 10). F: Akt phosphorylation (P-Akt) after treatment of cardiomyocyte suspensions
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to the microsomal fraction (Fig. 1B and C). Increased
CD36 translocation to the sarcolemma was associated
with increased basal LCFA uptake (Fig. 1D). Furthermore,
short-term (20-min) insulin treatment stimulated LCFA
and glucose uptake into cardiomyocytes in the low-fat diet
but not the high-fat diet condition (Fig. 1D and E). In-
sulin-induced Akt phosphorylation was also disturbed
in the high-fat diet condition (Supplementary Fig. 1E;
quantification in Fig. 1F).
Focusing on v-ATPase, the protein expression levels
of the V0 subunit a2 and V1 subunit B2 were unaf-
fected by the diet (Fig. 1G and H). As a readout of
v-ATPase function, we measured cellular accumulation
of the divalent weak base chloroquine, which becomes
specifically trapped in acidic organelles (21). For calibration
of this assay, we used bafilomycin-A, a potent v-ATPase in-
hibitor (20-min incubation). The bafilomycin-A–sensitive
component of the total cellular chloroquine accumulation
reflects v-ATPase activity. In low fat–diet cardiomyocytes,
the bafilomycin-A–sensitive component presents 62% of cel-
lular chloroquine accumulation (Fig. 1I). Whereas the bafilo-
mycin-A–insensitive component was unaltered in high fat–
diet cardiomyocytes, the bafilomycin-A–sensitive component
was decreased by 52%, thereby indicating a halfway inhibi-
tion of v-ATPase upon lipid overload. v-ATPase function
was also assessed with the fluorescent pH indicator
LysoSensor DND-189 in combination with two-photon
microscopy. Application of LysoSensor to low fat–diet
cardiomyocytes yielded a particulate staining pattern
(gray dots, Fig. 1J). Subsequent incubation with bafilomy-
cin-A resulted in a nearly complete disappearance of the
dots within ,20 min, suggesting that LysoSensor spe-
cifically visualizes organelles that are acidified by
v-ATPase. Importantly, the number of dots per cell in
comparison with the low-fat condition was much lower in
high fat–diet cardiomyocytes (Fig. 1K). Taken together,
the biochemical and microscopic methods both indicate
that v-ATPase function is inhibited in the lipid-overloaded
heart.
To investigate a possible causal link between v-ATPase
inhibition and increased CD36-mediated LCFA uptake,
cardiomyocytes from low- and high fat–diet rats were
incubated with bafilomycin-A (20 min) before substrate
uptake assays. Bafilomycin-A caused LCFA uptake to in-
crease to a similar level as insulin treatment of low fat–
diet cardiomyocytes, whereas no significant effect of the
inhibitor was observed in high fat–diet cardiomyocytes
(Fig. 1C). Hence, the mechanism of increased basal
LCFA uptake in high fat–diet cardiomyocytes might
include v-ATPase inhibition. Short-term treatment with
bafilomycin-A did not alter glucose uptake (Fig. 1C).
Therefore, CD36 trafficking is regulated by v-ATPase
function, whereas GLUT4 is not.
The main LCFA species of the lard-based high-fat
diet, which was used for the described animal studies,
is palmitate. Thus, we next investigated the palmitate-
induced changes in v-ATPase activity in cultured cardio-
myocytes. After 48 h, the high-palmitate culturing
condition induced an elevation in surface CD36 content
without changing CD36 total expression, indicating
increased CD36 translocation to the sarcolemma (Fig.
2A and B). Accordingly, LCFA uptake (Fig. 2C) and tri-
acylglycerol content (Fig. 2F) were increased upon high-
palmitate treatment, whereas insulin-stimulated LCFA/
glucose uptake and Akt phosphorylation were decreased
and contractile function was impaired (Fig. 2C–E and G).
Moreover, we observed a 60% decrease in v-ATPase func-
tion in cardiomyocytes treated with high palmitate versus
low palmitate (bafilomycin-A–sensitive chloroquine accu-
mulation) (Fig. 2H). Similar results were seen in mouse-
derived HL-1 cardiomyocytes upon lipid oversupply (Sup-
plementary Fig. 2). Hence, cellular palmitate oversupply
decreases v-ATPase function and leads to insulin resis-
tance and contractile dysfunction.
Palmitate Oversupply Causes v-ATPase Inhibition
Before the Onset of Insulin Resistance
Primary cardiomyocytes were exposed to variable periods
of high-palmitate culturing. We assessed v-ATPase func-
tion (by chloroquine accumulation) as well as LCFA/
glucose uptake and Akt/S6 phosphorylation in the
absence/presence of insulin. From the chloroquine data
(Fig. 3A), the bafilomycin-A–sensitive component was de-
duced as readout of v-ATPase activity (Supplementary Fig.
3A). The insulin-sensitive component was similarly calcu-
lated for substrate uptake and Akt/S6 phosphorylation
status (Supplementary Fig. 3B–E). Under low-palmitate
culturing conditions, endosomal pH, substrate uptake,
and insulin sensitivity did not change (Fig. 3A–E and
Supplementary Fig. 3A–E). In contrast, high-palmitate
culturing induced a rapid 34% decrease in v-ATPase func-
tion within the first hour, which was followed by a slower
rate of decline (Fig. 3A). In addition, basal LCFA uptake
increased by 1.5-fold within the first hour, with no fur-
ther increase thereafter (Fig. 3B). This rapid increase in
basal LCFA uptake was accompanied by a rapid loss of
insulin-sensitive LCFA uptake (Fig. 3B and Supplementary
Fig. 3B). Reductions in insulin-sensitive glucose uptake
without/with 100 nmol/L Ins (LFD: n = 4; HFD: n = 4). G and H: Protein expression of v-ATPase subunit a2 or B2 in cardiomyocytes (LFD:
n = 4; HFD: n = 4). I: Chloroquine (CHLQ) accumulation in cardiomyocytes treated without/with BafA for 15 min (LFD: n = 5; HFD: n = 6). J:
LysoSensor imaging in cardiomyocytes from LFD and HFD rats treated without BafA (basal) and with BafA for 15 min. Representative
microscopic images are displayed for each condition. K: Quantification is expressed as the number of dots per cell (LFD: n = 6; HFD: n = 6;
5 cells were analyzed from each cardiomyocyte preparation). Values are displayed as mean6 SEM. *P< 0.05. Data were normalized to Lys
(B and C), LFD/basal (F ), LFD (G and H), or to LFD/BafA (I and K).
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(Fig. 3C and Supplementary Fig. 3C) and phosphorylation
of Akt (Fig. 3D and Supplementary Fig. 3D and E) and S6
(Fig. 3E and Supplementary Fig. 3D and F) occurred much
later, namely, after 14 h of high-palmitate culturing. In
conclusion, high-palmitate induces a set of early changes
starting within 1 h and a set of later changes occurring
after 14 h (Fig. 3F). Hence, v-ATPase inhibition arises
well before the emergence of insulin resistance, which is
suggestive of v-ATPase inhibition as mediator of lipid-
induced insulin resistance.
Direct Inhibition of v-ATPase Induces Insulin
Resistance
Inhibition of v-ATPase in HL-1 cardiomyocytes was
achieved genetically via silencing of subunit B2 (which
also led to downregulation of subunit a2) and pharmaco-
logically via long-term bafilomycin-A treatment (Supplemen-
tary Fig. 4E, quantified in Fig. 4A and B). Both treatments
decreased v-ATPase function by .70% (bafilomycin-A–
sensitive chloroquine accumulation) (Fig. 4C and Supple-
mentary Fig. 4B). Subsequently, the effect of v-ATPase
Figure 2—Lipid overload induces v-ATPase inhibition in cultured cardiomyocytes. Rat cardiomyocytes were cultured for 48 h in media
containing low palmitate (LP) and high palmitate (HP). A: Cell surface abundance of CD36 protein using two-photon microscopy (n = 3;
representative images are shown). B: Protein expression of GLUT4 and CD36. Caveolin-3 (Cav3) was the loading control (n = 3). C–E: LCFA
and glucose uptake (n = 5) and Akt phosphorylation (P-Akt; n = 5) in cardiomyocytes treated without (basal)/with 100 nmol/L insulin (Ins) for
15 min. A representative blot is shown. F–H: Triacylglycerol content (n = 5), sarcomeric shortening at 1 Hz field stimulation (n = 5; imaging of
3 cells/condition), and chloroquine (CHLQ) accumulation in cardiomyocytes treated without (basal)/with 100 nmol/L bafilomycin-A (BafA) for
15 min (n = 5). Values are displayed as mean 6 SEM. *P < 0.05. Data were normalized to LP/basal (C and D), LP/Ins (E), LP (F ), or to
LP/BafA (H).
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inhibition on insulin sensitivity was investigated in cells
cultured with low palmitate concentrations that by them-
selves did not induce CD36 translocation or insulin resis-
tance (Fig. 4D–F and Supplementary Fig. 4C–G: compare
control [Ctrl] and low palmitate [LP]). Similar to high-
palmitate culturing, genetic and pharmacological v-ATPase
inhibition both caused a .1.6-fold increase in sarcolemmal
CD36 content under basal conditions, which occurred at the
cost of insulin-stimulated CD36 translocation (Fig. 4D and
Supplementary Fig. 4C). Furthermore, v-ATPase inhibition
(as well as high-palmitate treatment) caused a .40%
decrease of insulin-stimulated Akt/S6 phosphorylation in
HL-1 and primary cardiomyocytes (Fig. 4E and F and Sup-
plementary Fig. 4D–G and K–N). Mitochondrial parameters
and levels of reactive oxygen species were not altered (Sup-
plementary Fig. 4O–Q). Ultimately, v-ATPase inhibition
caused contractile dysfunction, as evident from the 64%
decrease in sarcomere shortening (Fig. 4G). Yet, the contrac-
tion acceleration time and the duration of relaxation
remained unaffected by bafilomycin-A (Fig. 4H and I).
High-palmitate treatment also induced a decrease of
sarcomere shortening of a similar magnitude without
changes in contraction kinetics (Fig. 4G–I). Taken to-
gether, direct v-ATPase inhibition causes increased CD36
translocation to the sarcolemma, insulin resistance, and
contractile dysfunction.
The Development of Insulin Resistance Induced
by v-ATPase Inhibition Requires CD36
CD36 was silenced in HL-1 cardiomyocytes using siRNA
(knockdown efficiency 50 6 11% [n = 3]) (Supplementary
Fig. 5A displays representative blot). As expected, CD36
silencing attenuated the development of the main fea-
tures of high palmitate–induced insulin resistance, such
as increased basal LCFA uptake and of losses of insulin-
stimulated LCFA/glucose uptake and Akt/S6 phosphory-
lation (Fig. 5A–D and Supplementary Fig. 5B–F). In the
low-palmitate condition, none of the parameters indicate
the development of insulin resistance, whereas long-term
bafilomycin-A treatment in this condition elicits changes
similar to those found during high-palmitate culturing
(Fig. 5A–E). Importantly, CD36 silencing fully prevented
the bafilomycin-A–induced changes in LCFA uptake and in-
sulin signaling (Fig. 5A–D and Supplementary Fig. 5B–F),
Figure 3—v-ATPase inhibition is an early event in lipid-induced insulin resistance. Rat cardiomyocytes were cultured with low palmitate
(LP) or high palmitate (HP) for 0, 1, 3, 8, 15, and maximum to 25 h. A: Chloroquine (CHLQ) accumulation in cardiomyocytes treated without
bafilomycin-A (BafA; LP and HP) and with 100 nmol/L BafA (LP/BafA and HP/BafA) for 15 min (n = 6). B and E: LCFA (n = 4–6) and glucose (n = 6)
uptake and phosphorylation of Akt (P-Akt; n = 6) and S6 (P-S6; n = 6) in cardiomyocytes treated without insulin (LP and HP) and with 100 nmol/L
insulin (LP/Ins and HP/Ins) for 15 min. Values are displayed as mean 6 SEM. #Significance of HP vs. HP/BafA (A) and of HP/Ins vs. (B–E); P <
0.05. ^Significance of HP vs. LP (A) and of HP/Ins vs. LP/Ins (B–E); P< 0.05. Data were normalized to LP/t = 0 (A–C) or to LP/Ins/t = 0 (D and E). F:
Overview of the data shown in panels A–E to highlight v-ATPase inhibition and lipid accumulation as early events before onset of insulin resistance.
v-ATPase function is deduced from the degree of CHLQ accumulation and insulin signaling from the degree of Akt and S6 phosphorylation.
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therefore disclosing the requirement of CD36 for the devel-
opment of insulin resistance resulting from v-ATPase
inhibition. CD36 silencing also fully prevented the high
palmitate–induced loss of chloroquine accumulation
(Fig. 5E and Supplementary Fig. 5G), thus indicating that
CD36-mediated LCFA uptake is responsible for v-ATPase
inhibition. These findings were further confirmed in pri-
mary cardiomyocytes, in which an immunological CD36
Figure 4—Direct inhibition of v-ATPase causes insulin resistance and contractile dysfunction in cardiomyocytes. A–F: HL-1 cardiomyo-
cytes were transfected with negative control scrambled siRNA or with siRNA targeting v-ATPase B2 subunit mRNA (B2-kd). At 32 h
after transfection, cells were cultured under control condition (Ctrl), or with low palmitate (LP), high palmitate (HP), or LP enriched with
100 nmol/L bafilomycin-A (LP/BafA) for 16 h. A and B: Protein expression of v-ATPase a2 (n = 4) and B2 subunits (n = 6). C: Chloroquine
(CHLQ) accumulation in cardiomyocytes treated without (basal)/with 100 nmol/L BafA for 25 min (n = 4). D–F: Sarcolemmal (i.e., cell
surface) CD36 content (n = 6) and phosphorylation of Akt (P-Akt, n = 8) and S6 (P-S6, n = 4) in cardiomyocytes treated without (basal)/with
100 nmol/L insulin (Ins) for 30 min. G–I: Rat cardiomyocytes were incubated in LP, HP, or LP/BafA for 25 h. Several parameters of
contraction were determined upon 1 Hz electrostimulation: sarcomere shortening (G), the time from the onset of the contraction to its
peak (time to peak) (H), and the time of decay of the contraction to 50% of its peak (decay time) (n = 4; imaging of 5 cells/condition) (I).
Values are displayed as mean 6 SEM. *P < 0.05. Data were normalized to LP (A and B), LP/BafA (C ), LP/basal (D), or to LP/Ins (E and F ).
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blockade via monoclonal antibody clone 63 prevented lipid
accumulation and loss of contractility and v-ATPase function
(Fig. 5F–H). We previously demonstrated that application of
clone 63 preserved insulin sensitivity and contractile function
in high palmitate–treated cardiomyocytes via inhibiting LCFA
uptake (17). Thus, CD36-mediated LCFA uptake is required
for v-ATPase inhibition and subsequent development of in-
sulin resistance and contractile dysfunction.
Human Cardiomyocytes Display Reduced v-ATPase
Function Upon Lipid Oversupply
Human iPSCs were differentiated into iPSC-CMs. Fourteen
days after the cardiomyocyte differentiation protocol was
initiated, .30% of the cells displayed spontaneous contrac-
tions, and the cardiospecific proteins myosin heavy chain
(a-isoform; MYH6) and cardiac troponin T (TNNT2) were
upregulated by 4.5- and 2.8-fold, respectively (Fig. 6A).
Similar to rodent cardiomyocytes (Figs. 1–5), iPSC-CMs de-
veloped the main features of insulin resistance upon high-
palmitate culturing: loss of insulin-stimulated LCFA/glucose
uptake and increased basal LCFA uptake, as well as loss of
insulin-stimulated Akt/S6 phosphorylation (Fig. 6B–D and
Supplementary Fig. 6A and B). Moreover, iPSC-CMs cultured
with high palmitate display loss of chloroquine accumulation
(Fig. 6E and Supplementary Fig. 6C). Therefore, the mecha-
nism of lipid-induced v-ATPase inhibition leading to insulin
Figure 5—Direct v-ATPase inhibition requires CD36 to develop insulin resistance and contractile dysfunction. A–E: HL-1 cardiomyocytes
(HL-1) were transfected with negative control scrambled siRNA or siRNA targeting CD36 mRNA (CD36-kd). At 32 h after transfection, cells
were cultured under control condition (Ctrl), or with high palmitate (HP), low palmitate (LP), or LP enriched with 100 nmol/L bafilomycin-A
(LP/BafA) for 16 h. A–D: LCFA (n = 5) and glucose (n = 5) uptake and phosphorylation of Akt (P-Akt; n = 6) and S6 (P-S6; n = 6) in HL-1
treated without (basal)/with 100 nmol/L insulin (Ins) for 30 min. E: Chloroquine (CHLQ) accumulation in HL-1 treated without (basal)/with
100 nmol/L BafA for 25 min (n = 6). F–H: Rat cardiomyocytes were incubated for 48 h with LP, HP, or HP with addition of 0.83 mg/mL anti–
CD36 clone 63 (aCD36). F: Triacylglycerol content (n = 5). G: Sarcomere shortening upon 1 Hz electrostimulation (n = 5). H: CHLQ
accumulation in cardiomyocytes treated without (basal)/with 100 nmol/L BafA (25 min) (n = 3). Values are displayed as mean 6 SEM.
*P < 0.05. Data were normalized to LP/basal (A and B), LP/Ins (C and D), LP/BafA (E ), or to LP (F and H).
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resistance appears conserved between species and thus ap-
plicable to the human heart.
Lipid-Induced v-ATPase Inhibition Is Caused
by Disassembly of the V0/V1 Subcomplexes
In earlier studies in yeast, reversible disassembly of
v-ATPase into its two subcomplexes, V0 and V1, was de-
scribed as a main mechanism of regulation of this protein
(13,15). Thus, HL-1 cardiomyocytes were cultured in
high-palmitate and control media, subsequently lysed in
the presence of mild detergents, and used for immuno-
precipitation with antibodies against the a2 or B2 sub-
units of v-ATPase. To assess the degree of assembly, we
exploited that a2 is part of the V0 subcomplex and that B2
is part of the V1 subcomplex. For both immunoprecipita-
tions, we observed that the degree of coimmunoprecipi-
tation with the other subunit under high-palmitate
culturing conditions was markedly lower than under basal
conditions (Fig. 7A), indicating V0/V1 disassembly.
We also applied subcellular fractionation to study the
V0/V1 assembly status. HL-1 cardiomyocytes were fraction-
ated into subcellular membranes and cytoplasm. The a2
subunit, as an indicator of the membrane-bound V0 sub-
complex, was found predominantly in the membrane frac-
tion (Fig. 7B). As part of the soluble V1 subcomplex, B2
markedly shifted from the membranous to the cytoplasmic
fraction upon high-palmitate culturing versus the control
condition (Fig. 7B). CD36 silencing prevented this shift of B2
from membranes to the cytoplasm (Fig. 7B). Together, these
findings indicate that lipid overexposure inhibits v-ATPase by
means of V0/V1 disassembly in a CD36-dependent manner.
Oleate Induces v-ATPase Inhibition but Does Not
Produce Insulin Resistance
Whereas palmitate is the most abundant saturated LCFA in
food, oleate is the predominant unsaturated LCFA. Oleate
inhibited v-ATPase activity in a similar manner as palmi-
tate (Fig. 8A). Yet, oleate induced triacylglycerol accumula-
tion but not insulin resistance (Fig. 8B and C).
DISCUSSION
The obtained results led us to formulate the following
conclusions: 1) Upon palmitate overload in cardiomyo-
cytes, v-ATPase activity decreases, leading to endosomal
alkalinization and thereafter to the onset of insulin re-
sistance and contractile dysfunction. 2) Palmitate-induced
v-ATPase inhibition involves V0/V1 disassembly and re-
quires CD36-mediated lipid uptake. 3) Oleate inhibits
v-ATPase to increase its uptake and subsequent storage
without causing insulin resistance. These aspects are fur-
ther discussed below.
Lipid-Induced v-ATPase Inhibition Precedes the Onset
of Insulin Resistance
Feeding rats a high-fat diet causes increased CD36 trans-
location to the sarcolemma and increased LCFA uptake,
followed by lipid accumulation, impaired insulin signaling
and insulin-stimulated glucose uptake, cardiac morpholog-
ical changes, and, finally, contractile dysfunction (8). In the
current study, the lipid-induced manifestations occurred in
conjunction with v-ATPase inhibition in rodent and human
cardiomyocytes upon lipid oversupply in vivo and in vitro
(Figs. 1, 2, and 6). Importantly, v-ATPase inhibition is an
Figure 6—Inhibition of v-ATPase replicates in human iPSC-CMs upon lipid overload. Human iPSC-CMs were cultured for 16 h in control
(Ctrl) or high-palmitate (HP) media. A: mRNA expression of MYH6 and TNNT2 in iPSC-CM vs. undifferentiated iPSC (n = 3). B–D: LCFA and
glucose uptake (n = 4) and phosphorylation of Akt (P-Akt) and S6 (P-S6) (n = 3; representative blots are displayed) in human iPSC-CMs
treated without (basal)/with 100 nmol/L insulin (Ins) for 30 min. Loading control: insulin receptor-b (IRb). E: Chloroquine (CHLQ) accumu-
lation in human iPSC-CM treated without (basal)/with 100 nmol/L bafilomycin-A (BafA) for 25 min. Values are displayed as mean 6 SEM.
*P < 0.05. Data were normalized to iPSC (A), Ctrl/basal (B and C), or to Ctrl/BafA (E).
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early event already occurring within 1 h after high-palmitate
addition that is simultaneous with a 1.5-fold increase in
myocellular LCFA uptake (Fig. 3 and Supplementary
Fig. 3). This rapid increase in basal LCFA uptake upon
the start of the high-palmitate treatment occurred at the
cost of insulin-stimulated LCFA uptake, which was com-
pletely blunted (Fig. 3B). Furthermore, high palmitate–
induced CD36 translocation renders the cells insensitive
to further insulin-stimulated CD36 translocation (Fig.
4D). Hence, an insulin-responsive CD36-containing
endosomal subcompartment might provide the source of
CD36 for translocation in lipid-overexposed cells. Nota-
bly, the impairment of insulin signaling and insulin-
stimulated glucose uptake followed much later (i.e., at
14 h after high-palmitate addition), indicating that
v-ATPase inhibition and CD36 translocation precede the
high palmitate–induced insulin resistance. These pre-
sent results are furthermore in good agreement with
our recent in vivo findings (22), where we observed rapid
increases in CD36 translocation to the sarcolemma and in
myocellular LCFA uptake, accumulation of triacylglycerol
and diacylglycerol (2–3 days), and a delayed impairment
in insulin signaling and GLUT4 translocation (.21 days).
Therefore, the processes that underlie the progression
from lipid accumulation into insulin resistance appear
complex and more time consuming than the relatively
fast occurring v-ATPase inhibition and consequent accel-
eration of CD36-mediated lipid uptake.
v-ATPase Inhibition Requires CD36 to Cause Insulin
Resistance and Contractile Dysfunction
The early onset of v-ATPase inhibition in lipid-induced
insulin resistance is suggestive of a causal involvement.
Direct evidence for a causal role of v-ATPase in lipid-
induced insulin resistance was obtained by 1) siRNA-
mediated silencing of v-ATPase and 2) long-term bafilomycin-A
treatment of cardiomyocytes in the presence of a low
amount of extracellular palmitate. Both strategies markedly
inhibited v-ATPase function, increased CD36 translocation
to the sarcolemma, and caused insulin resistance in a sim-
ilar manner as in high palmitate–treated cardiomyocytes.
With respect to contractile activity, v-ATPase inhibition in
cardiomyocytes caused a marked decrease in sarcomere
shortening, which is of similar magnitude as seen upon
high-palmitate treatment of cardiomyocytes. Moreover,
no changes occurred in contraction acceleration or relaxa-
tion time, making it unlikely that v-ATPase inhibition neg-
atively affects sarcomere shortening via a general toxic
action mechanism. Such a general toxic effect would not
only decrease the contraction amplitude but also increase
the relaxation time, as seen, for example, by mitochondrial
inhibition (23). Hence, our investigations causally link
v-ATPase inhibition not only to lipid-induced insulin re-
sistance but also to contractile dysfunction, thereby suggest-
ing that endosomal alkalinization underlies the metabolic
and functional alterations that are known characteristics
of lipid-induced cardiomyopathy.
Figure 7—Lipids induce inhibition of v-ATPase via its disassembly into V0 and V1 subcomplexes. HL-1 cardiomyocytes were transfected
with negative control scrambled siRNA or siRNA targeting CD36 mRNA (CD36-kd). At 32 h after transfection, cells were cultured for 16 h in
control medium (Ctrl) or with high palmitate (HP) and subsequently used for immunoprecipitation (IP) (A) or fractionation (B). A: Content of
v-ATPase subunits a2 and B2 in cell lysates (L) and in IPs using control IgG or antibodies capturing a2 and B2 (n = 3). The dotted lines
between the lanes indicate that these lanes were not adjacent to each other in the original gel, but nonetheless, were derived from the same
blots. B: Content of a2 and B2 in cytoplasmic fraction (C) and membrane fraction (M). GAPDH was the loading control for C, and caveolin-3
(Cav3) was the loading control for M (n = 3–7). B2 content of the cytoplasmic fraction was normalized against GAPDH and B2 content of the
membrane fraction against Cav3. Immunoblots are representative results.
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Figure 8—LCFA specificity and mechanism of lipid-induced v-ATPase inhibition. HL-1 cardiomyocytes (HL-1) were cultured under control
condition (Ctrl), with high palmitate (HP) or high oleate (HO) for 16 h. A: Chloroquine (CHLQ) accumulation in HL-1 treated without/with
100 nmol/L bafilomycin-A (BafA) for 25 min (n = 6). B: Triacylglycerol content (n = 6). C: Phosphorylation of Akt (P-Akt; n = 3) and S6 (P-S6;
n = 3) in cardiomyocytes treated without/with 100 nmol/L insulin (Ins) for 30 min. Cav3, caveolin-3; LO, low oleate; LP, low palmitate. Values
are displayed as mean 6 SEM. *P < 0.05. D: Schematic presentation of lipid-induced v-ATPase inhibition shows the consequences for
insulin sensitivity and contractile function. When the LCFA supply of oleate or palmitate is low, CD36 is primarily found in endosomes.
Furthermore, the v-ATPase V0 subcomplex, which is integral to the endosomal membrane, is assembled with the cytosolic V1 subcomplex,
allowing for acidification of the endosomal lumen. In this situation, the available LCFA is metabolized to meet the immediate energy
demand. Elevated extracellular LCFA supply triggers a series of events: 1) Increased CD36-mediated LCFA uptake results in elevated
intramyocellular LCFA levels. 2) LCFA causes the V1 and V0 subcomplexes to dissociate. 3) Therefore, V1 is shifted toward the cytoplasm.
4) The disassembly of v-ATPase leads to endosomal alkalinization. Increased endosomal pH triggers the translocation of CD36 vesicles to
the sarcolemma. Upon chronic lipid oversupply, where LCFA uptake surpasses the metabolic needs, further processes are set in motion. 5)
The lipid-induced increase in sarcolemmal CD36 feeds forward to further increased LCFA uptake and progressive lipid storage. 6) Palmitate
overload culminates into loss of insulin sensitivity and contractile function.
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How is v-ATPase inhibited by lipid overexposure? We
speculated on a causal role of CD36-mediated LCFA
uptake. Indeed, CD36 downregulation prevented high
palmitate–induced v-ATPase inhibition (Fig. 5E and H)
(i.e., pointing to impairment of v-ATPase function as a
consequence of CD36-mediated LCFA uptake). Moreover,
CD36 downregulation prevented increased LCFA uptake
(Fig. 5B), insulin resistance (Fig. 5C and D, and Supple-
mentary Fig. 5D–F), and contractile dysfunction (Fig. 5H).
Taken together, we describe a novel v-ATPase–CD36 in-
terplay showing its critical involvement in the develop-
ment of lipid-induced insulin resistance and contractile
dysfunction.
Cycles of assembly/disassembly appeared to be the
main mechanism of regulation of v-ATPase activity in
yeast (13,15). Hence, we speculated that lipids cause
v-ATPase disassembly into the two subcomplexes, V0
(that remains integral within the endosomal membrane)
and V1 (that will drift away into the cytoplasm). Indeed,
using two different methods (immunoprecipitation and
subcellular fractionation), we demonstrated that lipids in-
duce disassembly of v-ATPase and migration of V1 into
the cytoplasm (Fig. 7). Together, this indicates v-ATPase
as a possible lipid sensor in cardiomyocytes.
Oleate Inhibits v-ATPase Function Without Causing
Insulin Resistance
Oleate and palmitate alike inhibited v-ATPase activity.
However, downstream of v-ATPase, oleate exerted differ-
ent cellular actions than palmitate: oleate led to triacyl-
glycerol accumulation but did not elicit insulin resistance,
as also previously observed (24,25). What are the main
differences between these LCFAs that could explain the
observations? In particular, palmitate uptake may lead to
ceramide accumulation (24), which has been linked to the
development of insulin resistance (11). Conversely, oleate
uptake may be coupled to storage within “inert” lipid
droplets and/or could exert cardioprotective roles (26).
With respect to the mechanism of v-ATPase inhibition,
which likely is similar for oleate and palmitate, we searched
for a feasible answer to explain how lipids might cause
v-ATPase disassembly. Interestingly, v-ATPase disassembly
in neuronal cells appears to be induced by palmitoylation
(27). Given that various proteins undergo palmitoylation
and oleoylation at the same cysteine residue (28), the dis-
assembly signal might include long-chain fatty acylation at a
specific cysteine within one of the v-ATPase subunits. Fur-
ther studies are warranted to clarify the exact regulation of
v-ATPase assembly/disassembly by lipids in cardiomyocytes.
Proposed Model
We identify v-ATPase V0/V1 disassembly as a trigger of in-
creased CD36 translocation and thus describe a novel func-
tion of v-ATPase. Further, CD36-mediated lipid uptake
upon lipid supply feeds forward to increased CD36 trans-
location to the sarcolemma and further increased lipid
uptake. Accordingly, chronic lipid oversupply by inhibiting
v-ATPase gives rise to a vicious cycle of accelerated
myocellular lipid accumulation, which, in the case of pal-
mitate, sets the heart on a road to insulin resistance and
contractile dysfunction (Fig. 8). Because the mechanism
of lipid-induced v-ATPase inhibition is conserved in hu-
man cardiomyocytes, the identification of pharmacological
agents that stabilize the assembly of v-ATPase V1/V0 sub-
complexes may be considered as a possible novel strategy
to combat cardiac lipid overload.
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